Medivir Clears The Decks For Clinical Focus, Cuts All Preclinical Projects

Medivir outlines plans to cut costs, reduce headcount and streamline priorities as the biotech focuses solely on four assets in clinical development.

Uli Hacksell
Medivir Acting CEO Uli Hacksell • Source: Medivir AB

More from Business

More from Scrip